C OSBORNE to Survival Rate
This is a "connection" page, showing publications C OSBORNE has written about Survival Rate.
Connection Strength
0.176
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
Score: 0.033
-
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12.
Score: 0.024
-
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51.
Score: 0.021
-
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
Score: 0.016
-
A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5.
Score: 0.016
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9.
Score: 0.010
-
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004 Sep 01; 10(17):5670-6.
Score: 0.010
-
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9.
Score: 0.008
-
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
Score: 0.007
-
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
Score: 0.006
-
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May; 16(5):1669-76.
Score: 0.006
-
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
Score: 0.006
-
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
Score: 0.005
-
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
Score: 0.004
-
Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104.
Score: 0.004